CombiGene conducts a private placement of MSEK 4
April 24, 2020
CombiGene AB (publ) (”CombiGene” or the ”Company”) has today resolved to conduct a private placement of
CombiGene AB (publ) (”CombiGene” or the ”Company”) has today resolved to conduct a private placement of
CombiGene AB (“CombiGene” or the “Company”) has completed the rights issue of shares and warrants, so
The Board of Directors in Combigene AB (“Combigene” or the “Company”), reg. no. 556403-3818, resolved on
The Board of Directors in Combigene AB (“Combigene” or the “Company”), reg. no. 556403-3818, has today,
CombiGene AB (publ) (“CombiGene” or “the Company”) today announces the outcome of the exercise period of
The board of directors of CombiGene AB (publ) (”CombiGene”) has, on the basis of an authorisation
CombiGene AB (publ) (”CombiGene” or ”the Company”) concluded a preferential rights issue of units amounting to
In connection with the completed preferential rights issue in CombiGene AB (publ) (”CombiGene” or ”the Company”),
The units issued upon the board’s decision on 22 August 2018 consisted of both shares and
BioStock interviews CEO Jan Nilsson concerning the issue and the future To interview (in Swedish) >>